Capricor Therapeutics, Inc. (CAPR) 股票分析

公司概述

Capricor Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. The firm functions within the healthcare sector, specifically the biotechnology industry, where it focuses on advancing pipeline candidates from pre-clinical stages toward clinical trials and potential commercialization. This entity employs a workforce of 231 individuals to execute its research and development strategy, reflecting a mid-sized operational scale typical of late-stage biotech firms. With a market capitalization of $1.82 billion, the company holds a significant valuation relative to its current financial performance, as indicated by a lack of reported annual revenue in the trailing twelve months; this valuation structure suggests that the market price is primarily driven by the perceived future potential of its lead product candidate, the Der, rather than current cash flow generation.

财务健康

The company reports a net income of $-105,043,944 and an EBITDA of $-106,253,088 for the trailing twelve months, while revenue and free cash flow data are not available for the TTM period, with free cash flow specifically noted at $-39,600,748. The substantial gap between the reported net income and the near-zero revenue figures reveals a cost structure heavily weighted towards research, development, and clinical trial expenses rather than sales and marketing costs. Free cash flow stands at $-39,600,748, indicating that the company is consuming cash reserves to fund its operations and development pipeline, which limits immediate financial flexibility but is characteristic of clinical-stage biotechs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the absence of positive profit generation and the high proportion of costs relative to any minimal revenue recognized. The balance sheet holds $318.13 million in cash against $14.52 million in debt, resulting in a debt-to-equity ratio of 4.75, which suggests a leveraged position where equity is the primary financing source for operations. Despite the high debt-to-equity ratio, the current ratio is 9.01, indicating robust short-term liquidity as current assets significantly exceed current liabilities. Return on equity is -46.6% and return on assets is -25.7%, metrics that reveal management is currently generating negative returns on shareholder and asset bases due to the heavy investment in the clinical pipeline.

估值评估

The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -83.18, implying that the market is pricing the stock based on anticipated future earnings that are expected to be negative in the near term. The price-to-book ratio stands at 5.93, indicating that the market values the company at a significant premium over its tangible book value, a common characteristic for clinical-stage biotechnologies with high intangible asset value. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and the EV/EBITDA of -14.25, further reflect the speculative nature of the valuation where earnings are not yet positive. The 52-week high is $40.37 and the 52-week low is $4.30, placing the current trading price at a specific point within this wide range that reflects significant volatility and investor sentiment swings. The beta value of 0.48 indicates that the stock's price volatility is less than the broader market, suggesting lower systematic risk relative to large-cap indices despite the high leverage and speculative valuation.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of earnings growth speed relative to revenue expansion at this specific point in time. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources into research and development rather than distributing cash to shareholders. The absence of a dividend payout ratio confirms that the company prioritizes capital allocation toward building the clinical pipeline over providing current income to investors. Overall, the growth and income profile is defined by zero current profitability and zero dividend distribution, relying entirely on the successful advancement of its therapeutic candidates to generate future value.